Trinity Biotech

Trinity Biotech Enterprise Value

The Enterprise Value (EV) of Trinity Biotech (TRIB) as of Nov 11, 2026 is 147.19 M USD. In the previous year, Enterprise Value (EV) was 109.94 M USD — a change of 33.88% (higher).

Enterprise Value

147.19 MUSD

YoY

33.88%

Last updated:

Enterprise Value (EV) of Trinity Biotech is 2025 147.19 M USD. Enterprise Value (EV) of Trinity Biotech was 2024 109.94 M USD. It decreases by 33.88% higher compared to the previous year.

The Trinity Biotech Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
66.13 M USD
Jan 1, 2019
100.12 M USD
Jan 1, 2020
91.36 M USD
Jan 1, 2021
87.59 M USD
Jan 1, 2022
79.97 M USD
Jan 1, 2023
78.08 M USD
Jan 1, 2024
109.94 M USD
Jan 1, 2025
147.19 M USD
The Trinity Biotech Enterprise Value history
YEAREnterprise ValueYoY
147.19 MUSD+33.88%
109.94 MUSD+40.80%
78.08 MUSD-2.36%
79.97 MUSD-8.70%
87.59 MUSD-4.12%
91.36 MUSD-8.75%
100.12 MUSD+51.40%
66.13 MUSD+27.36%
51.92 MUSD+52.69%
34.00 MUSD+225.77%
10.44 MUSD-46.04%
19.34 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Enterprise Value (EV) of Trinity Biotech is 147.19 M USD in 2025.

Enterprise Value (EV) of Trinity Biotech changed from 109.94 M USD to 147.19 M USD, representing a 33.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Trinity Biotech

All Key Metrics — Trinity Biotech